港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

巨子生物

80.500

+0.5000.63%

成交量：158.95萬

成交額：1.28億

市值：862.16億

市盈率：35.66

高：81.200

開：79.100

低：79.100

收：80.000

資料載入中...

總覽公司新聞公告

鉅子生物：2024年公司收入達55.4億元，同比增長57%

【國元研究】鉅子生物（2367.HK）2024年年報點評——大單品驅動收入利潤高增，新品佈局穩步推進

鉅子生物營收超50億元，打開重組膠原蛋白市場一個可復美就夠了？

【券商聚焦】東吳證券維持鉅子生物(02367)“買入”評級指其品牌力和產品力領先未來拓展肌膚煥活可期

與薇婭深度綁定，鉅子生物財報亮眼難掩“拿證”無進展

【大行評級｜花旗：上調鉅子生物目標價至78.1港元維持“買入”評級】花旗發表研報指，鉅子生物2024財年淨利潤增長42%，符合預期；收入增長57%，超出預期，抵銷了較高的銷售與分銷費用。該行提及，鉅子生物管理層目標於2025財年實現收入增長25%至28%，淨利潤目標增長21%至24%。此外，管理層對今年首季表現感到滿意，特別是婦女節促銷，令管理層對實現全年目標有信心。該行將鉅子生物目標價由68.2港元上調至78.1港元，維持“買入”評級。

鉅子生物(2367.HK)2024年年報點評：大單品驅動收入利潤高增新品佈局穩步推進

鉅子生物去年業績暴增，但八成多依賴可復美，研發佔比下滑

南方都市报

花旗：鉅子生物去年淨利潤增長符預期升目標價至78.1港元

花旗：鉅子生物(02367)去年淨利潤增長符預期升目標價至78.1港元

《大行》花旗：鉅子生物(02367.HK)去年淨利潤增長符預期升目標價至78.1元

阿斯达克财经

高盛：升鉅子生物目標價至72港元重申“買入”評級

高盛：升鉅子生物(02367)目標價至72港元重申“買入”評級

異動解讀 | 鉅子生物盤中大跌6.03%，南向資金連續減持或為主因

鉅子生物(02367)2024年淨利同比增長42.1% 擬派末期股息及特別股息合計1.1942元人民幣

鉅子生物(02367)發佈年度業績股東應佔溢利20.62億元同比增加42.1% 持續加大研發投入

鉅子生物03月26日獲主力加倉24萬元

鉅子生物03月21日主力淨流出628萬元散户資金買入

國聯民生證券：社服順週期回升趨勢顯現 IP+、AI+創造新機遇

一週IPO觀察：鉅子生物上市大漲，子不語、多想雲招股，蝸牛遊戲赴美上市

财经自媒体

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02367/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02367","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02367\",,,,,undefined,":{"symbol":"02367","market":"HK","secType":"STK","nameCN":"巨子生物","latestPrice":80.5,"timestamp":1746173305030,"preClose":80,"halted":0,"volume":1589493,"delay":0,"floatShares":1071000000,"shares":1071000000,"eps":2.2572501098874693,"marketStatus":"休市中","change":0.5,"latestTime":"05-02 16:08:25","open":79.1,"high":81.2,"low":79.1,"amount":127954799,"amplitude":0.02625,"askPrice":80.5,"askSize":11600,"bidPrice":80.35,"bidSize":800,"shortable":3,"etf":0,"ttmEps":2.2138858680714857,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":7,"adr":0,"listingDate":1667491200000,"exchange":"SEHK","adjPreClose":80,"dividendRate":0.01205,"openAndCloseTimeList":[[1746149400000,1746158400000],[1746162000000,1746172800000]],"volumeRatio":0.2528733909568474,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02367\",,,,,undefined,":{"symbol":"02367","floatShares":1071000000,"roa":"21.92%","roe":"35.88%","lyrEps":2.25725,"volumeRatio":0.2528733909568474,"shares":1071000000,"dividePrice":0.97,"high":81.2,"amplitude":0.02625,"preClose":80,"low":79.1,"week52Low":35,"pbRate":"11.29","psRate":"14.48","week52High":81.8,"institutionHeld":0,"latestPrice":80.5,"committee":-0.870968,"eps":2.2572501098874693,"divideRate":0.01205,"volume":1589493,"delay":0,"ttmEps":2.2138858680714857,"open":79.1,"prevYearClose":49.9,"prevWeekClose":77.1,"prevMonthClose":80,"prevQuarterClose":70.45,"fiveDayClose":77.95,"twentyDayClose":70.45,"sixtyDayClose":56.85},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02367\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523931363","title":"鉅子生物：2024年公司收入達55.4億元，同比增長57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2523931363","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523931363?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 09:08","pubTimestamp":1743383280,"startTime":"0","endTime":"0","summary":"　　巨子生物2024年年度业绩发布会：公司2024年度业绩发布会展示了公司强劲的财务表现与业务进展。2024年公司收入达55.4亿元，同比增长57%，净利润20.6亿元，同比增长42%，净利率维持在37.2%的高水平。公司计划派息12.4亿元，其中末期股息每股0.602亿元，特别股息每股0.592亿元。研发支出1.1亿元，同比增长42.1%，拥有188项在研项目和167项专利。可复美品牌收入45.4亿元，同比增长62.9%，可丽金品牌收入8.4亿元，同比增长36.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-03-31/doc-inerpcsy1364194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2488822045.USD","BK1207","02367"],"gpt_icon":0},{"id":"2523008630","title":"【國元研究】鉅子生物（2367.HK）2024年年報點評——大單品驅動收入利潤高增，新品佈局穩步推進","url":"https://stock-news.laohu8.com/highlight/detail?id=2523008630","media":"国元研究","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523008630?lang=zh_tw&edition=fundamental","pubTime":"2025-03-29 07:30","pubTimestamp":1743204638,"startTime":"0","endTime":"0","summary":"文 |  李典徐梓童大单品驱动收入利润高增，新品布局稳步推进——巨子生物2024年年报点评事件：公司发布2024年年度报告。可复美胶原棒势能延续，焦点系列有望快速放量，新品布局稳步推进分品牌来看，24年可复美实现收入45.4亿元，同比增长62.9%。新品焦点系列聚焦皮肤亚状态人群，定位差异化，核心单品焦点面霜上新9个月实现天猫+抖音2.77亿GMV。可丽金实现收入8.4亿元，同比增长36.3%，新品胶卷眼霜、胶卷面霜贡献增量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250329075521a6a80976&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250329075521a6a80976&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1207","02367"],"gpt_icon":0},{"id":"2522493115","title":"鉅子生物營收超50億元，打開重組膠原蛋白市場一個可復美就夠了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2522493115","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522493115?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 16:35","pubTimestamp":1743150900,"startTime":"0","endTime":"0","summary":"巨子生物2024年财报显示，其收入增长57.2%至55.39亿元，净利润增长42.2%至20.62亿元，连续六年实现营收增长。这主要得益于市场需求的加速释放和企业经营战略的成功实施。巨子生物通过丰富产品矩阵和全渠道布局，进一步巩固了其市场地位。核心品牌可复美在医疗器械系列和功效护肤系列中均表现优异，特别是在天猫伤口敷料类目和医用敷料热卖榜上蝉联第一。在线上，巨子生物利用电商平台和社交平台进行营销推广，实现了显著的销售增长；线下则深耕医疗院线和药店渠道，并在CS/KA连锁、百货等开设门店，增强了品牌影响力。这些举措共同推动了巨子生物在重组胶原蛋白市场的领先地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250328164815972657cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250328164815972657cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367"],"gpt_icon":0},{"id":"2522513896","title":"【券商聚焦】東吳證券維持鉅子生物(02367)“買入”評級 指其品牌力和產品力領先 未來拓展肌膚煥活可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2522513896","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522513896?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 13:55","pubTimestamp":1743141343,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东吴证券发研指，巨子生物 24年营收55.4亿元，归母净利润20.6亿元，经调整净利润21.5亿元，经调整项主要为股权激励费用。可丽金定位抗老抗衰，与可复美的修复赛道形成差异化布局，新品胶卷面霜增长势头向上。该行表示，公司是我国重组胶原领域引领者，品牌力和产品力领先，未来拓展肌肤焕活可期。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1956181","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601555","02367"],"gpt_icon":0},{"id":"2522594830","title":"與薇婭深度綁定，鉅子生物財報亮眼難掩“拿證”無進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2522594830","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522594830?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 12:49","pubTimestamp":1743137340,"startTime":"0","endTime":"0","summary":"截至2024年末，巨子生物现金及现金等价物增至40.30亿元，较2023年25.04亿元同比增长61%，彰显财务稳健。巨子生物对此亦心知肚明。原料成本与竞品冲击，医美“拿证”无进展重组胶原蛋白是巨子生物的核心竞争力，但原料成本下降正动摇其高定价优势。巨子生物“进军医美”的口号已喊了数年，宣称储备四款Ⅲ类重组胶原针剂，两款预计2024年二季度获批，但至今无进展。巨子生物暂未回应降价计划，其技术领先优势恐被稀释。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032812503897261791&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032812503897261791&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367"],"gpt_icon":0},{"id":"2522564940","title":"【大行評級｜花旗：上調鉅子生物目標價至78.1港元 維持“買入”評級】花旗發表研報指，鉅子生物2024財年淨利潤增長42%，符合預期；收入增長57%，超出預期，抵銷了較高的銷售與分銷費用。該行提及，鉅子生物管理層目標於2025財年實現收入增長25%至28%，淨利潤目標增長21%至24%。此外，管理層對今年首季表現感到滿意，特別是婦女節促銷，令管理層對實現全年目標有信心。該行將鉅子生物目標價由68.2港元上調至78.1港元，維持“買入”評級。","url":"https://stock-news.laohu8.com/highlight/detail?id=2522564940","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522564940?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 10:27","pubTimestamp":1743128829,"startTime":"0","endTime":"0","summary":"花旗发表研报指，巨子生物2024财年净利润增长42%，符合预期；收入增长57%，超出预期，抵销了较高的销售与分销费用。该行提及，巨子生物管理层目标于2025财年实现收入增长25%至28%，净利润目标增长21%至24%。此外，管理层对今年首季表现感到满意，特别是妇女节促销，令管理层对实现全年目标有信心。该行将巨子生物目标价由68.2港元上调至78.1港元，维持“买入”评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/28102749103829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02367"],"gpt_icon":0},{"id":"2522549391","title":"鉅子生物(2367.HK)2024年年報點評：大單品驅動收入利潤高增 新品佈局穩步推進","url":"https://stock-news.laohu8.com/highlight/detail?id=2522549391","media":"国元证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522549391?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 00:00","pubTimestamp":1743091200,"startTime":"0","endTime":"0","summary":"事件：公司发布2024 年年度报告。可复美胶原棒势能延续，焦点系列有望快速放量，新品布局稳步推进分品牌来看，24 年可复美实现收入45.4 亿元，同比增长62.9%。明星产品胶原棒势能延续，健康的用户拉新和复购驱动增长，24年天猫+抖音双渠道GMV 近24 亿。新品焦点系列聚焦皮肤亚状态人群，定位差异化，核心单品焦点面霜上新9 个月实现天猫+抖音2.77 亿GMV。公司持续加强线上多平台人群破圈与场景运营，24 年可复美抖音GMV18 亿元，同比翻番增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250328163636a6a72ca9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250328163636a6a72ca9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1207","02367","LU2488822045.USD"],"gpt_icon":0},{"id":"2522830913","title":"鉅子生物去年業績暴增，但八成多依賴可復美，研發佔比下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2522830913","media":"南方都市报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522830913?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 21:12","pubTimestamp":1743081131,"startTime":"0","endTime":"0","summary":"3月27日，巨子生物发布2024年业绩公告。不过，巨子生物对可复美这一单一品牌的依赖度进一步上升，后者贡献了八成以上的收入。招引国际分析巨子生物业绩的研报中提到，2024年，可复美和可丽金在猫淘、京东、抖音的GMV共计达54亿元，同比增长57%。另外，在大部分国货美妆都在提高研发比例的当下，巨子生物2024年的研发成本占总收入的占比竟然在下降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250327213652a4440b38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250327213652a4440b38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","LU2488822045.USD","BK1207"],"gpt_icon":0},{"id":"2522634042","title":"花旗：鉅子生物去年淨利潤增長符預期 升目標價至78.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2522634042","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522634042?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 17:23","pubTimestamp":1743067380,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　花旗发布研报称，巨子生物（02367）2024财年净利润增长42%，符合预期；收入增长57%，超出预期，抵销了较高的销售与分销费用。该行将巨子生物目标价由68.2港元上调至78.1港元，维持“买入”评级。\n　　该行提及，巨子生物管理层目标于2025财年实现收入增长25%至28%，略低于预期的30%；净利润目标增长21%至24%，略低于预期的25%。此外，管理层对今年首季表现感到满意，特别是妇女节促销，令管理层对实现全年目标有信心。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：史丽君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2025-03-27/doc-inerauep8063604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02367"],"gpt_icon":0},{"id":"2522834471","title":"花旗：鉅子生物(02367)去年淨利潤增長符預期 升目標價至78.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2522834471","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522834471?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 16:46","pubTimestamp":1743065171,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，巨子生物(02367)2024财年净利润增长42%，符合预期;收入增长57%，超出预期，抵销了较高的销售与分销费用。该行将巨子生物目标价由68.2港元上调至78.1港元，维持“买入”评级。该行提及，巨子生物管理层目标于2025财年实现收入增长25%至28%，略低于预期的30%;净利润目标增长21%至24%，略低于预期的25%。此外，管理层对今年首季表现感到满意，特别是妇女节促销，令管理层对实现全年目标有信心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1268924.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367"],"gpt_icon":0},{"id":"2522234958","title":"《大行》花旗：鉅子生物(02367.HK)去年淨利潤增長符預期 升目標價至78.1元","url":"https://stock-news.laohu8.com/highlight/detail?id=2522234958","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522234958?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 16:10","pubTimestamp":1743063000,"startTime":"0","endTime":"0","summary":"花旗发表研报指，巨子生物(02367.HK) 2024财年净利润增长42%，符合预期；收入增长57%，超出预期，抵销了较高的销售与分销费用。该行提及，巨子生物管理层目标于2025财年实现收入增长25%至28%，略低于预期的30%；净利润目标增长21%至24%，略低于预期的25%。此外，管理层对今年首季表现感到满意，特别是妇女节促销，令管理层对实现全年目标有信心。该行将巨子生物目标价由68.2元上调至78.1元，维持“买入”评级。(js/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-27 12:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20221209170600934_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20221209170600934_s.jpg"],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1428854/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02367"],"gpt_icon":0},{"id":"2522701310","title":"高盛：升鉅子生物目標價至72港元 重申“買入”評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2522701310","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522701310?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 15:27","pubTimestamp":1743060420,"startTime":"0","endTime":"0","summary":"　　高盛发布研报称，巨子生物去年下半年业务继续超出预期，将其2025至2027财年净利润预测微调不足1%，目前料今年销售及净利润同比增长28%与24%，至71亿及25.5亿元人民币。该行对其目标价由64港元上调至72港元，重申“买入”评级。　　报告显示，公司销售及净利润各同比增长56%与38%，超过该行预期8%与2%，并较市场预期高9%及5%。该行认为公司派息率达60%带来正面惊喜，意味着股息率达2%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2025-03-27/doc-inerapwk5143710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02367"],"gpt_icon":0},{"id":"2522314169","title":"高盛：升鉅子生物(02367)目標價至72港元 重申“買入”評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2522314169","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522314169?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 14:29","pubTimestamp":1743056998,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研报称，巨子生物(02367)去年下半年业务继续超出预期，将其2025至2027财年净利润预测微调不足1%，目前料今年销售及净利润同比增长28%与24%，至71亿及25.5亿元人民币。该行对其目标价由64港元上调至72港元，重申“买入”评级。报告显示，公司销售及净利润各同比增长56%与38%，超过该行预期8%与2%，并较市场预期高9%及5%。去年收入与净利润分别同比升57%及42%，亦均超出管理层的最新指引，分别高出该行预测4%和1%，及较市场预期高5%与3%。该行认为公司派息率达60%带来正面惊喜，意味着股息率达2%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1268802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367"],"gpt_icon":0},{"id":"1150492940","title":"異動解讀 | 鉅子生物盤中大跌6.03%，南向資金連續減持或為主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1150492940","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150492940?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 09:52","pubTimestamp":1743040369,"startTime":"0","endTime":"0","summary":"港股上市公司巨子生物今日盘中大跌6.03%，引发市场关注。此次股价下跌可能与近期南向资金持续减持有关。截至3月26日收盘，港股通共持有巨子生物14376.19万股，占流通股的13.88%。数据显示，该股近5个交易日下跌3.34%，港股通累计减持171.64万股；而在近20个交易日内，该股上涨8.54%，但港股通累计减持高达857.95万股。投资者应密切关注该公司后续发展及资金流向变化，谨慎评估投资风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 巨子生物盘中大跌6.03%，南向资金连续减持或为主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02367"],"gpt_icon":0},{"id":"2522980707","title":"鉅子生物(02367)2024年淨利同比增長42.1% 擬派末期股息及特別股息合計1.1942元人民幣","url":"https://stock-news.laohu8.com/highlight/detail?id=2522980707","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522980707?lang=zh_tw&edition=fundamental","pubTime":"2025-03-26 22:10","pubTimestamp":1742998212,"startTime":"0","endTime":"0","summary":"金吾财讯 | 巨子生物 发布截至2024年12月31日止年度业绩公告，报告期内实现收入55.39亿元人民币，同比增长57.2%；归母净利润20.62亿元，同比增长42.1%。每股基本盈利2.10元，去年同期为1.49元。拟派末期股息每股0.6021元，及特别股息0.5921元，合计1.1942元。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/M2UyZGNiNDRjZmIyOTFjZmIzN2JhMmQ2MDYyMzM5MDkyOTMyMQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/M2UyZGNiNDRjZmIyOTFjZmIzN2JhMmQ2MDYyMzM5MDkyOTMyMQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1955997","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367","BK1207","LU2488822045.USD"],"gpt_icon":0},{"id":"2522125805","title":"鉅子生物(02367)發佈年度業績 股東應佔溢利20.62億元 同比增加42.1% 持續加大研發投入","url":"https://stock-news.laohu8.com/highlight/detail?id=2522125805","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522125805?lang=zh_tw&edition=fundamental","pubTime":"2025-03-26 21:04","pubTimestamp":1742994278,"startTime":"0","endTime":"0","summary":"智通财经APP讯，巨子生物 发布截至2024年12月31日止年度业绩，该集团期内取得收入55.39亿元，同比增加57.2%;归属于母公司持有者盈利20.62亿元，同比增加42.1%;每股基本盈利2.1元;拟派发末期股息每股0.6021元及特别股息每股0.5921元。报告期内，公司研发支出达到人民币1.07亿元，同比增长42.1%，研发支出占收入比例1.9%。截至报告期末，集团拥有188项在研项目。截至报告期末，公司已获授权及申请中专利达到167项，其中报告期内新增74项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1268358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1207","02367","LU2488822045.USD"],"gpt_icon":1},{"id":"2522446478","title":"鉅子生物03月26日獲主力加倉24萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2522446478","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522446478?lang=zh_tw&edition=fundamental","pubTime":"2025-03-26 16:15","pubTimestamp":1742976959,"startTime":"0","endTime":"0","summary":"03月26日, 巨子生物股价涨3.03%，报收68.00元，成交金额2.27亿元，换手率0.33%，振幅4.77%，量比1.03。巨子生物今日主力资金净流入24万元，上一交易日主力净流入1018万元。该股近5个交易日下跌2.77%，主力资金累计净流入395万元；近20日主力资金累计净流入1.52亿元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250326165545a6a479c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250326165545a6a479c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","LU2488822045.USD","BK1207"],"gpt_icon":0},{"id":"2521470291","title":"鉅子生物03月21日主力淨流出628萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2521470291","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521470291?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 16:17","pubTimestamp":1742545038,"startTime":"0","endTime":"0","summary":"03月21日, 巨子生物股价跌0.85%，报收69.60元，成交金额2.25亿元，换手率0.31%，振幅5.63%，量比0.77。巨子生物今日主力资金净流出628万元，上一交易日主力净流入346万元。该股近5个交易日上涨1.91%，主力资金累计净流入601万元，其中3个交易日为股价下跌时净流入；近20日主力资金累计净流入1.55亿元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321170852a43c7444&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321170852a43c7444&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","LU2488822045.USD","BK1207"],"gpt_icon":0},{"id":"2520438022","title":"國聯民生證券：社服順週期回升趨勢顯現 IP+、AI+創造新機遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2520438022","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520438022?lang=zh_tw&edition=fundamental","pubTime":"2025-03-20 16:50","pubTimestamp":1742460631,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国联民生证券发布研报称，近日，中共中央办公厅、国务院办公厅印发《提振消费专项行动方案》，方案部署了相关提振消费的8方面30项重点任务。国联民生证券主要观点如下：近期顺周期跟踪：回升趋势显现2025年以来同比数据有比较明显的改善：1)人服：新增招聘贴数2025年3月以来每周均有明显的改善。风险提示消费复苏不及预期风险，市场竞争加剧超风险，AI应用效果不及预期风险，海外复盘研究存在局限性风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1264730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IP","BK1249","162414","LU1481599808.USD","BK1227","09896","BK4588","BK4585","601456","BK4136","BK1207","161027","01318","BK0276","LU1481600234.SGD","LU2463526074.USD","06181","LU1487256676.USD","BK1246","LU2488822045.USD","02367"],"gpt_icon":1},{"id":"2519878125","title":"一週IPO觀察：鉅子生物上市大漲，子不語、多想雲招股，蝸牛遊戲赴美上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2519878125","media":"财经自媒体","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519878125?lang=zh_tw&edition=fundamental","pubTime":"2025-03-14 17:18","pubTimestamp":1741943880,"startTime":"0","endTime":"0","summary":"港股IPO观察截止2022年的第45周，港交所1家新股上市，4家招股，6家递交上市申请。截至2022年7月15日，今年港交所新上市60家，共募资856.58亿港元。公司引入3名基石投资者，合共认购认购2260万美元的发售股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-03-14/doc-inepritp9633129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4085","BK1142","SNAL","BK1114","02420","02367","LU2488822045.USD","06696","BK1207","BK1137"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02367\",params:#limit:5,,,undefined,":[{"date":"2025-06-17","symbol":"02367","amount":0.5921,"announcedDate":"2025-03-26","type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2025-06-18","defaultRemindTime":1750123800000,"name":"巨子生物","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-29","payableDate":"2025-06-18","currency":"CNY","dateTimestamp":1750089600000,"payDate":"2025-08-29"},{"date":"2025-03-26","symbol":"02367","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742952600000,"name":null,"time":"盤後","dateTimestamp":1742918400000,"actualEps":null},{"date":"2024-08-19","symbol":"02367","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"盤後","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-06-17","symbol":"02367","amount":0.97,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2024-06-18","defaultRemindTime":1718587800000,"name":"巨子生物","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-05","payableDate":"2024-06-18","currency":"HKD","dateTimestamp":1718553600000,"payDate":"2024-07-05"},{"date":"2024-03-25","symbol":"02367","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02367\",market:\"HK\",,,undefined,":[{"executeDate":"2024-06-17","recordDate":"2024-06-18","paymentDate":"2024-07-05","value":0.97,"currency":"HKD"},{"executeDate":"2025-06-17","recordDate":"2025-06-18","paymentDate":"2025-08-29","value":0.5921,"currency":"CNY"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02367\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.4737,"buy":0.5263,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5263,"analysts":19,"updateTime":1745424000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02367\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02367","date":"2025-05-02","current":37.455761,"percent":0.891447,"low":18.546195,"twenty":25.86929,"median":29.382648,"eighty":34.212713,"high":60.214956,"avg":30.51844,"sd":6.565878,"marketCap":82402510032},"quantilePoints":[{"date":"2022-11-04","current":28.694216,"twenty":26.512834,"median":26.542085,"eighty":27.833364,"marketCap":25968654960},{"date":"2022-11-11","current":35.577583,"twenty":27.402937,"median":34.819032,"eighty":37.211633,"marketCap":32485133920},{"date":"2022-11-18","current":30.409033,"twenty":29.071802,"median":32.325114,"eighty":36.373143,"marketCap":27670720360},{"date":"2022-11-25","current":29.089974,"twenty":29.309257,"median":30.328688,"eighty":34.970742,"marketCap":26260437600},{"date":"2022-12-02","current":29.440115,"twenty":28.58665,"median":29.786096,"eighty":33.378719,"marketCap":27035200000},{"date":"2022-12-09","current":33.170723,"twenty":28.69893,"median":30.328688,"eighty":33.541593,"marketCap":30744000000},{"date":"2022-12-16","current":33.617702,"twenty":28.859591,"median":31.890871,"eighty":33.525219,"marketCap":31085600000},{"date":"2022-12-23","current":32.235512,"twenty":29.23003,"median":32.061881,"eighty":33.375102,"marketCap":29816800000},{"date":"2022-12-30","current":35.028223,"twenty":29.440115,"median":32.235512,"eighty":33.644993,"marketCap":32793600000},{"date":"2023-01-06","current":34.259259,"twenty":29.598569,"median":32.356077,"eighty":33.906187,"marketCap":32403200000},{"date":"2023-01-13","current":37.514633,"twenty":29.683286,"median":32.593587,"eighty":35.138095,"marketCap":36160800000},{"date":"2023-01-20","current":39.320225,"twenty":29.767789,"median":33.170723,"eighty":36.075015,"marketCap":37576000000},{"date":"2023-01-27","current":41.405428,"twenty":29.847916,"median":33.242723,"eighty":36.22764,"marketCap":39576800000},{"date":"2023-02-03","current":46.017337,"twenty":30.125824,"median":33.502098,"eighty":37.981351,"marketCap":44212800000},{"date":"2023-02-10","current":48.646066,"twenty":30.280481,"median":33.687805,"eighty":39.317619,"marketCap":46457600000},{"date":"2023-02-17","current":47.305048,"twenty":30.475064,"median":33.964048,"eighty":41.148897,"marketCap":44749600000},{"date":"2023-02-24","current":46.898265,"twenty":30.969524,"median":34.88282,"eighty":44.591745,"marketCap":43822400000},{"date":"2023-03-03","current":48.206405,"twenty":31.89643,"median":35.69024,"eighty":46.759698,"marketCap":45335200000},{"date":"2023-03-17","current":60.214956,"twenty":31.932315,"median":36.041848,"eighty":47.552658,"marketCap":56754400000},{"date":"2023-03-24","current":51.699724,"twenty":32.016899,"median":36.568073,"eighty":48.347792,"marketCap":49288000000},{"date":"2023-03-31","current":40.925047,"twenty":32.156582,"median":37.514633,"eighty":48.347792,"marketCap":46848000000},{"date":"2023-04-06","current":40.652856,"twenty":32.21578,"median":38.432644,"eighty":48.279626,"marketCap":46506400000},{"date":"2023-04-14","current":37.246115,"twenty":32.289273,"median":38.307612,"eighty":48.226605,"marketCap":42651200000},{"date":"2023-04-21","current":33.385259,"twenty":32.343692,"median":38.098031,"eighty":47.893759,"marketCap":38210400000},{"date":"2023-04-28","current":30.285025,"twenty":32.289273,"median":37.591448,"eighty":47.642868,"marketCap":34404000000},{"date":"2023-05-05","current":26.161165,"twenty":31.945964,"median":37.33158,"eighty":47.490756,"marketCap":29768000000},{"date":"2023-05-12","current":30.574645,"twenty":30.692284,"median":36.23263,"eighty":47.274687,"marketCap":34550400000},{"date":"2023-05-19","current":31.711515,"twenty":30.746535,"median":35.923479,"eighty":47.115193,"marketCap":35331200000},{"date":"2023-05-25","current":31.182824,"twenty":30.822604,"median":35.69024,"eighty":46.935066,"marketCap":34599200000},{"date":"2023-06-02","current":32.039153,"twenty":30.742861,"median":35.028223,"eighty":46.759698,"marketCap":35428800000},{"date":"2023-06-09","current":32.262222,"twenty":30.684805,"median":34.15987,"eighty":46.167812,"marketCap":35624000000},{"date":"2023-06-16","current":32.772734,"twenty":30.742861,"median":33.693297,"eighty":45.892894,"marketCap":36014400000},{"date":"2023-06-23","current":31.032471,"twenty":30.757557,"median":33.682729,"eighty":45.395124,"marketCap":33916000000},{"date":"2023-06-30","current":31.360803,"twenty":30.757557,"median":33.502098,"eighty":44.617559,"marketCap":33964800000},{"date":"2023-07-07","current":31.376956,"twenty":30.759705,"median":33.358016,"eighty":44.488487,"marketCap":33916000000},{"date":"2023-07-14","current":31.254408,"twenty":30.81937,"median":33.206723,"eighty":42.385946,"marketCap":34257600000},{"date":"2023-07-21","current":29.61115,"twenty":30.759705,"median":32.931722,"eighty":41.535665,"marketCap":32305600000},{"date":"2023-07-28","current":31.165322,"twenty":30.717545,"median":32.723027,"eighty":41.405428,"marketCap":33964800000},{"date":"2023-08-04","current":32.76763,"twenty":30.739187,"median":32.639512,"eighty":41.393979,"marketCap":35770400000},{"date":"2023-08-11","current":32.773868,"twenty":30.757557,"median":32.603384,"eighty":41.176747,"marketCap":35575200000},{"date":"2023-08-18","current":30.610294,"twenty":30.757557,"median":32.513854,"eighty":41.037499,"marketCap":32988800000},{"date":"2023-08-25","current":31.726668,"twenty":30.759705,"median":32.346784,"eighty":40.925047,"marketCap":34208800000},{"date":"2023-09-01","current":27.573424,"twenty":30.671209,"median":32.32831,"eighty":40.652856,"marketCap":36697600000},{"date":"2023-09-08","current":26.75169,"twenty":30.572064,"median":32.277824,"eighty":40.648282,"marketCap":35184800000},{"date":"2023-09-15","current":25.993592,"twenty":30.285025,"median":32.235512,"eighty":40.62978,"marketCap":34452800000},{"date":"2023-09-22","current":25.737943,"twenty":29.809068,"median":32.045764,"eighty":40.128892,"marketCap":33964800000},{"date":"2023-09-29","current":25.066298,"twenty":29.656075,"median":31.997803,"eighty":39.81665,"marketCap":33135200000},{"date":"2023-10-06","current":25.484582,"twenty":29.406098,"median":31.918666,"eighty":39.533705,"marketCap":33672000000},{"date":"2023-10-13","current":24.08012,"twenty":28.952772,"median":31.841433,"eighty":39.348774,"marketCap":31768800000},{"date":"2023-10-20","current":22.598372,"twenty":28.090884,"median":31.767659,"eighty":39.309801,"marketCap":29768000000},{"date":"2023-10-27","current":22.348635,"twenty":27.619397,"median":31.711663,"eighty":39.282609,"marketCap":29426400000},{"date":"2023-11-03","current":25.394448,"twenty":27.541831,"median":31.642548,"eighty":39.168886,"marketCap":33525600000},{"date":"2023-11-10","current":25.843419,"twenty":27.016595,"median":31.492944,"eighty":38.901953,"marketCap":34111200000},{"date":"2023-11-17","current":25.355932,"twenty":26.744612,"median":31.467436,"eighty":38.544946,"marketCap":33769600000},{"date":"2023-11-24","current":25.803053,"twenty":26.578324,"median":31.402883,"eighty":38.289787,"marketCap":34648000000},{"date":"2023-12-01","current":25.805078,"twenty":26.361375,"median":31.373452,"eighty":38.186355,"marketCap":34794400000},{"date":"2023-12-08","current":23.911147,"twenty":26.187226,"median":31.314709,"eighty":38.124793,"marketCap":32110400000},{"date":"2023-12-15","current":23.015122,"twenty":25.978956,"median":31.279712,"eighty":37.928033,"marketCap":31085600000},{"date":"2023-12-22","current":23.970526,"twenty":25.934891,"median":31.256547,"eighty":37.726838,"marketCap":32354400000},{"date":"2023-12-29","current":25.605578,"twenty":25.922833,"median":31.253927,"eighty":37.637537,"marketCap":34745600000},{"date":"2024-01-05","current":24.881987,"twenty":25.805078,"median":31.237017,"eighty":37.514633,"marketCap":33525600000},{"date":"2024-01-12","current":25.701327,"twenty":25.757517,"median":31.165322,"eighty":37.417045,"marketCap":34648000000},{"date":"2024-01-19","current":24.032983,"twenty":25.700075,"median":31.138965,"eighty":37.246115,"marketCap":32354400000},{"date":"2024-01-26","current":24.563567,"twenty":25.531167,"median":31.049171,"eighty":36.903516,"marketCap":32940000000},{"date":"2024-02-02","current":22.773078,"twenty":25.419215,"median":30.993085,"eighty":36.23263,"marketCap":30500000000},{"date":"2024-02-09","current":24.329361,"twenty":25.355932,"median":30.81937,"eighty":36.207681,"marketCap":32744800000},{"date":"2024-02-16","current":25.846624,"twenty":25.369207,"median":30.758631,"eighty":36.108181,"marketCap":34794400000},{"date":"2024-02-23","current":26.457355,"twenty":25.369207,"median":30.717545,"eighty":35.899805,"marketCap":35428800000},{"date":"2024-03-01","current":26.003824,"twenty":25.387892,"median":30.635655,"eighty":35.803782,"marketCap":34843200000},{"date":"2024-03-08","current":26.210688,"twenty":25.395134,"median":30.572064,"eighty":35.667709,"marketCap":35136000000},{"date":"2024-03-15","current":30.241869,"twenty":25.409765,"median":30.44783,"eighty":35.490153,"marketCap":40504000000},{"date":"2024-03-22","current":31.217759,"twenty":25.435494,"median":30.569793,"eighty":35.18968,"marketCap":41772800000},{"date":"2024-03-28","current":26.416103,"twenty":25.461641,"median":30.551779,"eighty":34.970062,"marketCap":41528800000},{"date":"2024-04-05","current":26.713065,"twenty":25.484582,"median":30.44783,"eighty":34.88282,"marketCap":41968000000},{"date":"2024-04-12","current":27.194611,"twenty":25.506915,"median":30.285025,"eighty":34.259259,"marketCap":42748800000},{"date":"2024-04-19","current":29.268508,"twenty":25.516475,"median":30.168532,"eighty":34.060481,"marketCap":45969600000},{"date":"2024-04-26","current":29.89571,"twenty":25.531167,"median":29.89571,"eighty":33.867614,"marketCap":46896800000},{"date":"2024-05-03","current":31.286129,"twenty":25.569811,"median":29.89571,"eighty":33.72816,"marketCap":49044000000},{"date":"2024-05-10","current":35.317002,"twenty":25.600357,"median":30.150227,"eighty":34.911901,"marketCap":51288800000},{"date":"2024-05-17","current":33.551674,"twenty":25.608792,"median":30.245106,"eighty":35.034138,"marketCap":48653600000},{"date":"2024-05-24","current":33.729665,"twenty":25.66112,"median":30.409033,"eighty":35.021714,"marketCap":48800000000},{"date":"2024-05-31","current":34.458991,"twenty":25.697876,"median":30.512617,"eighty":34.936642,"marketCap":49905929000},{"date":"2024-06-07","current":35.513458,"twenty":25.700826,"median":30.572064,"eighty":35.034138,"marketCap":51369298000},{"date":"2024-06-14","current":33.485895,"twenty":25.715973,"median":30.610294,"eighty":35.023883,"marketCap":48392099000},{"date":"2024-06-21","current":32.121521,"twenty":25.745773,"median":30.694377,"eighty":34.964455,"marketCap":46323198000},{"date":"2024-06-28","current":32.099848,"twenty":25.775731,"median":30.739187,"eighty":34.884174,"marketCap":46272737000},{"date":"2024-07-05","current":29.936022,"twenty":25.803458,"median":30.671209,"eighty":34.879736,"marketCap":43144155000},{"date":"2024-07-12","current":29.087996,"twenty":25.812746,"median":30.592469,"eighty":34.858532,"marketCap":41983552000},{"date":"2024-07-19","current":27.898783,"twenty":25.84406,"median":30.569793,"eighty":34.80307,"marketCap":40267878000},{"date":"2024-07-26","current":27.412372,"twenty":25.847354,"median":30.44783,"eighty":34.722361,"marketCap":39712807000},{"date":"2024-08-02","current":26.870727,"twenty":25.853895,"median":30.347362,"eighty":34.692602,"marketCap":38905431000},{"date":"2024-08-09","current":29.53175,"twenty":25.868681,"median":30.263126,"eighty":34.580226,"marketCap":43043233000},{"date":"2024-08-16","current":27.651468,"twenty":25.880225,"median":30.20526,"eighty":34.54918,"marketCap":40318339000},{"date":"2024-08-23","current":20.295155,"twenty":25.847354,"median":30.132576,"eighty":34.503268,"marketCap":39157736000},{"date":"2024-08-30","current":21.43279,"twenty":25.766624,"median":29.936022,"eighty":34.476088,"marketCap":41630325000},{"date":"2024-09-06","current":20.565575,"twenty":25.695677,"median":29.843348,"eighty":34.445054,"marketCap":39965112000},{"date":"2024-09-13","current":18.849184,"twenty":25.540828,"median":29.786096,"eighty":34.363297,"marketCap":36533764000},{"date":"2024-09-20","current":20.082561,"twenty":25.484582,"median":29.694562,"eighty":34.259259,"marketCap":39157736000},{"date":"2024-09-27","current":24.850231,"twenty":25.394448,"median":29.657792,"eighty":34.060481,"marketCap":48745326000},{"date":"2024-10-04","current":29.382648,"twenty":25.395362,"median":29.624666,"eighty":34.023673,"marketCap":57374157000},{"date":"2024-10-10","current":27.207172,"twenty":25.409765,"median":29.557165,"eighty":33.926357,"marketCap":52782206000},{"date":"2024-10-18","current":27.08831,"twenty":25.435494,"median":29.436062,"eighty":33.784845,"marketCap":52277596000},{"date":"2024-10-25","current":27.691447,"twenty":25.469288,"median":29.344363,"eighty":33.707844,"marketCap":53438199000},{"date":"2024-11-01","current":28.012496,"twenty":25.497982,"median":29.274876,"eighty":33.690002,"marketCap":54094192000},{"date":"2024-11-08","current":29.463901,"twenty":25.512651,"median":29.272452,"eighty":33.684759,"marketCap":56465859000},{"date":"2024-11-15","current":26.265769,"twenty":25.52529,"median":29.194481,"eighty":33.660087,"marketCap":49956390000},{"date":"2024-11-22","current":26.278217,"twenty":25.56015,"median":29.088985,"eighty":33.628618,"marketCap":49956390000},{"date":"2024-11-29","current":26.561468,"twenty":25.595136,"median":29.046664,"eighty":33.578085,"marketCap":50461000000},{"date":"2024-12-06","current":27.316407,"twenty":25.595136,"median":28.89327,"eighty":33.512207,"marketCap":51772986000},{"date":"2024-12-13","current":27.527865,"twenty":25.608792,"median":28.855293,"eighty":33.470601,"marketCap":52126213000},{"date":"2024-12-20","current":27.519045,"twenty":25.66112,"median":28.7635,"eighty":33.433798,"marketCap":51823447000},{"date":"2024-12-27","current":26.95045,"twenty":25.695677,"median":28.729978,"eighty":33.410147,"marketCap":50713305000},{"date":"2025-01-03","current":25.718533,"twenty":25.700075,"median":28.694216,"eighty":33.386493,"marketCap":48442560000},{"date":"2025-01-10","current":26.596222,"twenty":25.605578,"median":28.598093,"eighty":33.385259,"marketCap":49905929000},{"date":"2025-01-17","current":28.4557,"twenty":25.610934,"median":28.581538,"eighty":33.383573,"marketCap":53438199000},{"date":"2025-01-24","current":29.058848,"twenty":25.694577,"median":28.62658,"eighty":33.365541,"marketCap":54912816000},{"date":"2025-01-28","current":30.995109,"twenty":25.696776,"median":28.668851,"eighty":33.362531,"marketCap":58878741600},{"date":"2025-02-07","current":31.279146,"twenty":25.700576,"median":28.706002,"eighty":33.347316,"marketCap":59082122400},{"date":"2025-02-14","current":32.46032,"twenty":25.708209,"median":28.7635,"eighty":33.295849,"marketCap":61166775600},{"date":"2025-02-21","current":32.605291,"twenty":25.726297,"median":28.850334,"eighty":33.213923,"marketCap":61776918000},{"date":"2025-02-28","current":33.709306,"twenty":25.745773,"median":28.875802,"eighty":33.347316,"marketCap":63658190400},{"date":"2025-03-07","current":37.167941,"twenty":25.761386,"median":29.014465,"eighty":33.385999,"marketCap":70471447200},{"date":"2025-03-14","current":37.985438,"twenty":25.781535,"median":29.070262,"eighty":33.525362,"marketCap":72047648400},{"date":"2025-03-21","current":37.329923,"twenty":25.803863,"median":29.089974,"eighty":33.667635,"marketCap":70776518400},{"date":"2025-03-28","current":31.329348,"twenty":25.820414,"median":29.153791,"eighty":33.6911,"marketCap":69149472000},{"date":"2025-04-03","current":32.960917,"twenty":25.84406,"median":29.176551,"eighty":33.68679,"marketCap":72606945600},{"date":"2025-04-11","current":32.158951,"twenty":25.847354,"median":29.194481,"eighty":33.675182,"marketCap":70369756800},{"date":"2025-04-17","current":33.426462,"twenty":25.850275,"median":29.270028,"eighty":33.693297,"marketCap":73318778400},{"date":"2025-04-25","current":35.713683,"twenty":25.864757,"median":29.297766,"eighty":33.896985,"marketCap":78403298400},{"date":"2025-05-02","current":37.455761,"twenty":25.86929,"median":29.382648,"eighty":34.212713,"marketCap":82402510032}],"updateTime":1746299662420}}}